94 related articles for article (PubMed ID: 7669076)
1. Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues.
Rowlands MG; Budworth J; Jarman M; Hardcastle IR; McCague R; Gescher A
Biochem Pharmacol; 1995 Aug; 50(5):723-6. PubMed ID: 7669076
[TBL] [Abstract][Full Text] [Related]
2. Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity.
Rowlands MG; Parr IB; McCague R; Jarman M; Goddard PM
Biochem Pharmacol; 1990 Jul; 40(2):283-9. PubMed ID: 2165403
[TBL] [Abstract][Full Text] [Related]
3. Rationally designed analogues of tamoxifen with improved calmodulin antagonism.
Hardcastle IR; Rowlands MG; Houghton J; Parr IB; Potter GA; Jarman M; Edwards KJ; Laughton CA; Trent JO; Neidle S
J Med Chem; 1995 Jan; 38(2):241-8. PubMed ID: 7830266
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of protein kinase C and calmodulin by the geometric isomers cis- and trans-tamoxifen.
O'Brian CA; Ioannides CG; Ward NE; Liskamp RM
Biopolymers; 1990 Jan; 29(1):97-104. PubMed ID: 2158363
[TBL] [Abstract][Full Text] [Related]
5. Evidence that tamoxifen binds to calmodulin in a conformation different to that when binding to estrogen receptors, through structure-activity study on ring-fused analogues.
McCague R; Rowlands MG; Grimshaw R; Jarman M
Biochem Pharmacol; 1994 Oct; 48(7):1355-61. PubMed ID: 7945433
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C.
Carpenter C; Sorenson RJ; Jin Y; Klossowski S; Cierpicki T; Gnegy M; Showalter HD
Bioorg Med Chem; 2016 Nov; 24(21):5495-5504. PubMed ID: 27647375
[TBL] [Abstract][Full Text] [Related]
7. Homologs of idoxifene: variation of estrogen receptor binding and calmodulin antagonism with chain length.
Hardcastle IR; Rowlands MG; Grimshaw RM; Houghton J; Jarman M
J Med Chem; 1996 Feb; 39(4):999-1004. PubMed ID: 8632423
[TBL] [Abstract][Full Text] [Related]
8. Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells.
Gulino A; Barrera G; Vacca A; Farina A; Ferretti C; Screpanti I; Dianzani MU; Frati L
Cancer Res; 1986 Dec; 46(12 Pt 1):6274-8. PubMed ID: 3022916
[TBL] [Abstract][Full Text] [Related]
9. Antagonism of estrogen receptor and calmodulin association by antiestrogens is not dependent on an interaction with calmodulin.
Rowlands MG; Grimshaw R; Jarman M; Bouhoute A; Leclercq G
Biochem Pharmacol; 1997 Jan; 53(2):241-4. PubMed ID: 9037257
[TBL] [Abstract][Full Text] [Related]
10. Endoxifen is a new potent inhibitor of PKC: a potential therapeutic agent for bipolar disorder.
Ali SM; Ahmad A; Shahabuddin S; Ahmad MU; Sheikh S; Ahmad I
Bioorg Med Chem Lett; 2010 Apr; 20(8):2665-7. PubMed ID: 20227879
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of calmodulin and protein kinase C antagonists on bone resorption and acid transport activity.
Williams JP; Thames AM; McKenna MA; McDonald JM
Calcif Tissue Int; 2003 Sep; 73(3):290-6. PubMed ID: 14667143
[TBL] [Abstract][Full Text] [Related]
12. CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells.
Luo W; Sharif TR; Houghton PJ; Sharif M
Cell Growth Differ; 1997 Nov; 8(11):1225-40. PubMed ID: 9372245
[TBL] [Abstract][Full Text] [Related]
13. Effects of felodipine (a dihydropyridine calcium channel blocker) and analogues on calmodulin-dependent enzymes.
Walsh MP; Sutherland C; Scott-Woo GC
Biochem Pharmacol; 1988 Apr; 37(8):1569-80. PubMed ID: 2833901
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells.
Lavie Y; Zhang ZC; Cao HT; Han TY; Jones RC; Liu YY; Jarman M; Hardcastle IR; Giuliano AE; Cabot MC
Int J Cancer; 1998 Sep; 77(6):928-32. PubMed ID: 9714066
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of melanoma cell/matrix interaction by tamoxifen.
Mac Neil S; Wagner M; Kirkham PR; Blankson EA; Lennard MS; Goodall T; Rennie IG
Melanoma Res; 1993 Feb; 3(1):67-74. PubMed ID: 8471839
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase.
Lam HY
Biochem Biophys Res Commun; 1984 Jan; 118(1):27-32. PubMed ID: 6320825
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the role of signal transduction in attachment of ocular melanoma cells to matrix proteins: inhibition of attachment by calmodulin antagonists including tamoxifen.
Mac Neil S; Wagner M; Rennie IG
Clin Exp Metastasis; 1994 Nov; 12(6):375-84. PubMed ID: 7923990
[TBL] [Abstract][Full Text] [Related]
18. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Sharp SY; Rowlands MG; Jarman M; Kelland LR
Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of calmodulin antagonism by triphenylethylene antiestrogens.
Barrera G; Screpanti I; Paradisi L; Parola M; Ferretti C; Vacca A; Farina A; Dianzani MU; Frati L; Gulino A
Biochem Pharmacol; 1986 Sep; 35(17):2984-6. PubMed ID: 3017367
[No Abstract] [Full Text] [Related]
20. Estrogen-dependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative HCC38 cells is membrane-mediated and inhibited by tamoxifen.
Boyan BD; Sylvia VL; Frambach T; Lohmann CH; Dietl J; Dean DD; Schwartz Z
Endocrinology; 2003 May; 144(5):1812-24. PubMed ID: 12697687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
